Antony Currie and
Robert Cyran
explain why
Allergan's
$2.5 bln deal for
fat-freezing firm
Zeltiq offers more
certainty of cold,
hard cash than so
(more)
Antony Currie and Robert Cyran explain why Allergan's $2.5 bln deal for fat-freezing firm Zeltiq offers more certainty of cold, hard cash than some of its other recent acquisitions.
